Janux Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-55.59	-58.29	-63.06	-32.67	-6.78	-4
Depreciation & Amortization	2.03	1.96	0.84	0.11	0.01	0.01
Share-Based Compensation	20.16	20.01	17.2	6.91	0.07	0.01
Other Operating Activities	-18.1	-14.24	2.09	8.67	2.33	0.16
Operating Cash Flow	-51.5	-50.58	-42.92	-16.98	-4.37	-3.83
Capital Expenditures	-1.76	-1.85	-6.45	-1.48	0	0
Change in Investments	-144.43	-39.34	64.71	-339.48	0	0
Investing Cash Flow	-146.19	-41.19	58.27	-340.96	0	0
Share Issuance / Repurchase	380.14	59.55	0.5	205.98	0.07	0
Debt Issued / Paid	0	0	0	0	2.5	4
Other Financing Activities	-	-	-	180.55	8.95	-
Financing Cash Flow	380.14	59.55	0.5	386.52	11.52	4
Net Cash Flow	182.45	-32.22	15.84	28.59	7.16	0.17
Free Cash Flow	-53.26	-52.43	-49.37	-18.46	-4.37	-3.83
Free Cash Flow Margin	-730.93%	-648.58%	-573.24%	-507.51%	-	-
Free Cash Flow Per Share	-1.09	-1.19	-1.19	-0.78	-4.77	-5.72

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).